RECENT NEWS

I-SPY 2 Clinical Trial Results Announced at AACR 2016
San Francisco, CA—April 18, 2016

 

QuantumLeap Healthcare Collaborative announced Results from the I-SPY 2 TRIAL (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2) indicating that a neoadjuvant (presurgery) therapy combination of the antibody-drug conjugate trastuzumab emtansine (T-DM1; Kadcyla) and pertuzumab (Perjeta) was more beneficial than paclitaxel plus trastuzumab for women with HER2-positive invasive breast cancer. Research was presented today at the AACR Annual Meeting 2016, April 16-20.

Read More